RECOMMENDED FORMULA: This formula includes lutein, zeaxanthin, zinc, copper, vitamin C, and vitamin E to exactly match the nutrient formula recommended by the AMD experts at the National Eye ...

Bausch Health faces $21 billion in debt, with $10 billion due by 2027 and a $2.4 billion loan due next year. Private equity ...

Banks and private credit firms are competing to provide at least $5 billion of debt financing to help fund a potential buyout ...

Bausch + Lomb Co. (NYSE:BLCO – Get Free Report) has been assigned an average recommendation of “Moderate Buy” from the twelve ...

Monday was an eventful day for Bausch + Lomb (NYSE: BLCO). The eye care specialist's major piece of internal news was that it earned its latest Food and Drug Administration (FDA) approval.

Bausch & Lomb (BLCO) stock soars 8% in premarket as private equity firms TPG and Blackstone consider joint bid for the eyecare company.

In a report released today, Douglas Miehm from RBC Capital assigned a Buy rating to Bausch + Lomb Corporation (BLCO – Research Report), with a price target of $23.00. The company’s shares closed ...

Bausch + Lomb has teamed up with American sportscaster Erin Andrews to promote its dry eye disease treatment, launching the “Miebo ohh yeah” campaign to spread the word about the condition and ...

Bausch + Lomb (NYSE:BLCO – Free Report) had its price objective raised by Royal Bank of Canada from $20.00 to $23.00 in a report released on Tuesday morning, Benzinga reports. Royal Bank of Canada ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third ...

Continued progress on the buyout of Bausch & Lomb is lifting shares, with the stock up over 6% at the time of writing. Financial Times reported on Oct. 14 that two prominent figures involved in ...

In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...